Proceedings of the National Academy of Sciences · 2021 · 72 citations · 52 references
MedicineInfectious DiseasesPediatricsImmunizationPediatric Infectious DiseasesVaccinologyPediatric ImmunizationVaccinationVaccine-preventable DiseasesVector-based VaccinesViral VaccinesViral Vector VaccinesIntranasal ImmunizationPediatric VaccinationPediatric Vaccine DevelopmentPediatric Vaccine EfficacyPediatric Vaccine TrialsSars-cov-2 InfectionVectored VaccinesViral Vector Immunogenicity
Significance Pediatric SARS-CoV-2 infections, though generally mild, are associated with substantial morbidity and contribute to transmission dynamics. No SARS-CoV-2 vaccines are available for young children. Bovine/human parainfluenza virus 3 (B/HPIV3) vectors for intranasal immunization of children were evaluated previously in phase 1/2 studies and were well-tolerated in children as young as 2 mo of age. This manuscript describes a B/HPIV3 vector expressing a prefusion-stabilized version of the SARS-CoV-2 S protein (S-2P), and shows that a single intranasal dose is highly immunogenic and protective against SARS-CoV-2 challenge in the hamster model, the most robust SARS-CoV-2 challenge model available. Based on these results, B/HPIV3/S-2P represents a promising vaccine candidate for clinical evaluation as a pediatric vaccine for intranasal immunization against HPIV3 and SARS-CoV-2.
52
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou, Xing‐Lou Yang, Xian-Guang Wang et al. · Nature · 2020 · 23.3K citations · Full text
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett et al. · Science · 2020 · 9.8K citations · Full text